CP101の新興薬剤に関する洞察と市場予測：2032年

Finch Therapeuticsが開発中のCP101は、マイクロバイオーム機能不全に関連する病態を対象とした治験中の経口投与マイクロバイオーム治療薬です。CP101は、経口投与の腸溶性カプセルで完全なマイクロバイオームコミュニティを提供します。この薬剤はrCDIの予防を目的として後期臨床開発段階にあります。同社は、B型慢性肝炎の治療薬としてのCP101の評価を手始めに、マイクロバイオームの崩壊に関連する他の疾患への展開を計画しています。

最近、米国FDAはFinch TherapeuticsのCP101の治験新薬（IND）申請に対する臨床保留を解除しました。同社は、rCDI予防を目的としたCP101のPRISM4（第III相）試験で患者への投与を進めており、PRISM4からのトップラインデータは2024年上半期に出ると見込んでいます。

今後数年間で、クロストリジウムディフィシル感染症の市場シナリオは、世界中の広範な研究と医療支出の増加により変化することが予想されます。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、CP101の優位性に影響を与える可能性のある機会を模索しています。クロストリジウムディフィシル感染症に対する他の新興製品は、CP101に厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるCP101市場について調査し、市場の概要とともに、2025年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 クロストリジウムディフィシル感染症に対するCP101の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 CP101市場評価

• クロストリジウムディフィシル感染症に対するCP101の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるクロストリジウムディフィシル感染症に対するCP101の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: CP101, Clinical Trial Description, 2023
• Table 2: CP101, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: CP101 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: CP101 Market Size in the US, in USD million (2019-2032)
• Table 7: CP101 Market Size in Germany, in USD million (2019-2032)
• Table 8: CP101 Market Size in France, in USD million (2019-2032)
• Table 9: CP101 Market Size in Italy, in USD million (2019-2032)
• Table 10: CP101 Market Size in Spain, in USD million (2019-2032)
• Table 11: CP101 Market Size in the UK, in USD million (2019-2032)
• Table 12: CP101 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: CP101 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: CP101 Market Size in the United States, USD million (2019-2032)
• Figure 3: CP101 Market Size in Germany, USD million (2019-2032)
• Figure 4: CP101 Market Size in France, USD million (2019-2032)
• Figure 5: CP101 Market Size in Italy, USD million (2019-2032)
• Figure 6: CP101 Market Size in Spain, USD million (2019-2032)
• Figure 7: CP101 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: CP101 Market Size in Japan, USD million (2019-2032)

“"CP101 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about CP101 for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the CP101 for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the CP101 for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CP101 market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

CP101, being developed by Finch Therapeutics, is an investigational, orally administered microbiome drug for conditions linked to microbiome dysfunction. CP101 delivers complete microbiome communities in orally administered, enteric-release capsules. The drug is in late-stage clinical development for the prevention of rCDI. The company is planning to deploy CP101 to other conditions linked to microbiome disruption, starting with the evaluation of CP101 as a treatment for chronic hepatitis B.

Recently, the US FDA removed the clinical hold on Finch's Investigational New Drug (IND) application for CP101. The company has proceeded with patient dosing in the PRISM4 (Phase III) trial of CP101 for the prevention of rCDI, and anticipates topline data from PRISM4 in H1 2024.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the CP101 description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on CP101 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CP101 research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CP101.
• The report contains forecasted sales of CP101 for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for CP101 in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CP101 Analytical Perspective by DelveInsight

In-depth CP101 Market Assessment

This report provides a detailed market assessment of CP101 for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

CP101 Clinical Assessment

The report provides the clinical trials information of CP101 for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CP101 dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to CP101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CP101 in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of CP101 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CP101 in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of CP101?
• What is the clinical trial status of the study related to CP101 in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CP101 development?
• What are the key designations that have been granted to CP101 for clostridium difficile infection?
• What is the forecasted market scenario of CP101 for clostridium difficile infection?
• What are the forecasted sales of CP101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to CP101 for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. CP101 Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. CP101 Market Assessment

• 5.1. Market Outlook of CP101 in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of CP101 in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of CP101 in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of CP101 in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of CP101 in France for Clostridium difficile infection
  • 5.3.4. Market Size of CP101 in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of CP101 in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of CP101 in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of CP101 in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options